Bertech is addressing the need for a more patient-friendly, accurate and inexpensive diagnostic test for colorectal cancer (CRC) that is capable of detecting the disease in its early stages. Bertech is also addressing the need for treatment assays that assess the effectiveness of treatment modalities and provide post-treatment surveillance, as well as the need for new treatment options.
Bertech has in-licensed biomarker technologies and compounds to address these clinical needs and to advance the areas of cancer diagnostics, treatment assessment, post treatment monitoring and new CRC treatments.
Latest News >
- March 11, 2020 — Bertech’s Pivotal Trial Validates Blood Test for Colorectal Cancer
- February 26, 2013 — Dr. David Dureck joins Bertech Pharma’s Scientific Board of Advisors
- September 06, 2012 — Dr. David Evans and Dr. Randall Johnston join Bertech Pharma’s Scientific Board of Advisors